Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
HAYWARD, Calif., November 14, 2023--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL. The fireside chat will take place on Tuesday, November 28th, 2023 at 7:55am ET.
A live webcast of the fireside chat will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2α. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231114888556/en/
Contacts
Investor Inquiries
Pia Eaves
Head of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
